Search Results
Your search for The%20,The matches 7896 pages
Showing 51 - 100Second-Line Pembrolizumab Plus Lenvatinib in Pleural Mesothelioma
In a cohort of a Dutch single-center phase II study (PEMMELA) reported in The Lancet Oncology, Douma et al found that pembrolizumab plus lenvatinib was active in patients with pleural mesothelioma whose disease progressed after treatment with nivolumab plus ipilimumab. In cohort 1 in the trial,...
Lung Cancer Deaths Prevented and Life-Years Gained From Lung Cancer Screening: Current vs 100% Screening Uptake
In a study reported as a research letter in JAMA, Bandi et al compared estimated deaths prevented and life-years gained with current uptake vs 100% uptake of annual lung cancer screening in eligible U.S. individuals. Study Details The study used data obtained from the 2024 National Health Interview ...
FDA Approves Durvalumab With FLOT for Resectable Gastric/GEJ Adenocarcinoma
On November 25, 2025, the U.S. Food and Drug Administration (FDA) approved durvalumab (Imfinzi) in combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy as neoadjuvant and adjuvant treatment, followed by single-agent durvalumab, for the treatment of adult...
External Validation Confirms Ability of AI Model to Stratify Recurrence Risk in Early-Stage Lung Cancer
A machine learning–based survival model, incorporating preoperative CT images and routinely available clinical data, outperformed standard clinical staging systems in predicting recurrence after surgery in patients with lung cancer, especially in stage I, and showed correlations with established...
Zanzalintinib Plus Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer
The phase III STELLAR-303 trial evaluated the anti-VEGFR–related multitargeted tyrosine kinase inhibitor zanzalintinib in combination with the PD-L1 inhibitor atezolizumab vs the multikinase inhibitor regorafenib in patients with previously treated non–microsatellite instability (MSI)–high...
Proton vs Photon Radiation Therapy for Nonmetastatic Breast Cancer: Focus on Patient Perspective and Satisfaction
Health-related quality-of-life analyses for proton radiation therapy and photon radiation therapy in patients with nonmetastatic breast cancer showed similar impacts on quality of life with both treatments, according to findings from the phase III RadComp consortium trial. Shannon M. MacDonald, MD, ...
Treatment Advances in Malignant Hematology: 2025 Updates
The pace of therapeutic innovation in hematologic oncology continues to accelerate, moving clinical practice away from broad-spectrum chemotherapy and toward an era of highly personalized, biologically driven treatment. This transformation was the central theme of the 2025 National Comprehensive...
Primary Analysis Shows Survival Benefit With Bemarituzumab Plus Chemotherapy in Gastric or Gastroesophageal Junction Cancer
The addition of bemarituzumab, a first-in-class anti-FGFR2b antibody, to mFOLFOX6 chemotherapy significantly improved overall survival in patients with FGFR2b-overexpressing (≥ 10% tumor cell staining) unresectable, locally advanced or metastatic gastric or gastroesophageal junction cancer,...
Final Analysis Supports Use of Durvalumab Plus BCG Infusions in High-Risk Non–Muscle-Invasive Bladder Cancer
In patients with high-risk non–muscle-invasive bladder cancer, the addition of 1 year of the PD-L1 inhibitor durvalumab to standard induction and maintenance bacillus Calmette-Guérin (BCG) infusions led to a statistically significant and clinically meaningful improvement in disease-free survival...
European Society for Medical Oncology Congress 2025 Meeting Highlights
The European Society for Medical Oncology (ESMO) Congress 2025 in Berlin featured many important trials with the potential to significantly influence clinical practice and improve outcomes for patients with multiple tumor types. These studies highlighted the benefits of novel treatment combination...
Addition of Durvalumab to BCG After TURBT for BCG-Naive, High-Risk NMIBC
In the final analysis of the phase III POTOMAC trial reported in The Lancet, De Santis et al found that the addition of durvalumab to bacillus Calmette-Guérin (BCG) induction and maintenance improved disease-free survival in patients with high-risk non–muscle-invasive bladder cancer (NMIBC) who...
FDA Grants Accelerated Approval to Sevabertinib for Nonsquamous NSCLC
On November 19, the U.S. Food and Drug Administration (FDA) granted accelerated approval to sevabertinib (Hyrnuo), a kinase inhibitor, for adults with locally advanced or metastatic nonsquamous non–small cell lung cancer (NSCLC) whose tumors have HER2 tyrosine kinase domain (TKD) activating...
FDA Approves Selumetinib for Adults With NF1 With Symptomatic, Inoperable Plexiform Neurofibromas
On November 19, the U.S. Food and Drug Administration (FDA) approved selumetinib (Koselugo), a MEK inhibitor, for adults with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). In September 2025, the FDA approved selumetinib capsules and granules for...
Long-Term Survival With vs Without Postmastectomy Chest Wall Irradiation in Breast Cancer
As reported in the The New England Journal of Medicine by Kunkler et al, the phase III SUPREMO trial showed no significant difference in 10-year overall survival in women with breast cancer receiving vs not receiving postmastectomy chest-wall irradiation. Study Details In the international trial...
Quality Improvement Program Cuts Missed Radiation Appointments by 40%
A national quality improvement program led by the American College of Surgeons (ACS) found that transportation barriers and illness are among the top reasons patients with cancer miss critical radiation therapy appointments—and that providing hospitals and patients with structured support can...
Could a Liquid Biopsy Lead to Earlier Diagnoses for Numerous Cancer Types?
Routine screening is limited to only a few cancer types. New research indicates that routine liquid biopsy testing (multicancer early detection testing) could substantially reduce late-stage cancer diagnoses, allowing patients to receive treatment at earlier stages of disease, when they are more...
HER3-DXd in Patients With Active Brain Metastases From NSCLC and Breast Cancer
In the phase II TUXEDO-3 trial—reported in two articles in The Lancet Oncology—Fuereder et al and Bartsch et al found that the topoisomerase-1 HER3-targeting antibody-drug conjugate patritumab deruxtecan (HER3-DXd) was active in cohorts of patients with active brain metastases from advanced...
Reducing the Impact of Climate-Induced Events on Patients and Oncology Staff
Although 2023 made headlines as the hottest year in human history,1 drawing the world closer to breaching the goals outlined in the Paris Agreement to substantially reduce global greenhouse gas emissions to limit global warming to well below 2°C above preindustrial levels (and preferably to...
Safety and Benefit of Radiation Therapy for High-Risk Muscle-Invasive Bladder Cancer
Following cystectomy, patients with muscle-invasive bladder cancer at high risk for recurrence may safely be treated with radiotherapy and may achieve an improvement in locoregional control compared with observation. These findings, which come from the phase III BART trial presented in a plenary...
Intensity-Modulated Radiation Therapy vs Proton Therapy for Oropharyngeal Cancer
The phase III TORPEdO trial reported no meaningful differences between intensity-modulated radiation therapy (IMRT) and proton beam therapy at 1 year in terms of patient-reported quality of life, swallowing function, or feeding tube dependence for individuals with locally advanced oropharyngeal...
FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma
On November 6, 2025, the U.S. Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro) for adults with high-risk smoldering multiple myeloma. Efficacy of daratumumab and hyaluronidase as monotherapy vs active monitoring was evaluated in AQUILA, an open-label,...
A Serendipitous Fall May Have Saved My Life
In the spring of 2024, I was preparing to compete in a Half Ironman triathlon and was not surprised when I began experiencing tightness in my groin. I just figured it was the byproduct of specific endurance training I was doing in each discipline, including running, biking, and swimming, to get...
First-Line Ivonescimab or Tislelizumab Plus Chemotherapy in Advanced Squamous NSCLC
In an interim analysis of a Chinese phase III trial (HARMONi-6) reported in The Lancet, Chen et al found that the combination of ivonescimab—a bispecific antibody targeting PD-1 and VEGF—plus chemotherapy prolonged progression-free survival vs tislelizumab—an anti–PD-1 monoclonal antibody—plus...
Final Overall Survival Confirms Benefit of Durvalumab Plus FLOT in Resectable Gastric and Gastroesophageal Junction Adenocarcinomas
The addition of the PD-L1–targeting monoclonal antibody durvalumab to conventional perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) resulted in a statistically significant and clinically meaningful improvement in overall survival, with benefit seen...
New Report: Lung Cancer Advancements Are Saving More Lives Than Ever, but Funding Cuts May Hinder Progress
The American Lung Association has released its 2025 “State of Lung Cancer” report, which reveals great strides in efforts to end lung cancer—the leading cause of cancer-related deaths in the United States. This year, nearly 227,000 people in the United States will be diagnosed with lung cancer....
Study Finds Breast Cancer Risk Varies Between Different Hormonal Contraceptives
Some common hormonal contraceptives are linked to a slightly higher risk of breast cancer than others. This is shown by a new study from Uppsala University, in which researchers followed more than 2 million women and teenage girls in Sweden to identify how different hormonal contraceptives affect...
Diminishing the National Cancer Institute Threatens Americans
In an effort to reduce the size of government, the current administration has proposed an across the board 37% reduction1 in funding for the National Cancer Institute (NCI). This will result in approval of only 4% of applications2 from scientists at universities and cancer centers, with 96% of all ...
Zanzalintinib Plus Atezolizumab vs Regorafenib in Previously Treated Metastatic Colorectal Cancer Without MSI-H or dMMR Tumors
In a phase III trial (STELLAR-303) reported in The Lancet, Hecht et al found that the combination of the multitargeted tyrosine kinase inhibitor zanzalintinib and atezolizumab improved overall survival vs regorafenib in patients with previously treated relapsed or refractory metastatic colorectal...
Deep Learning and Mammography for Identifying Interval Breast Cancers
A deep learning algorithm developed for processing digital screening mammograms, Mirai, was able to detect interval breast cancers and identify women who would benefit from more frequent screenings, according to the results of a UK retrospective study published in Radiology. “If we called back 20% ...
Advanced Urothelial Carcinoma: PPARG Inhibitor Shows Preliminary Efficacy
Each year, nearly 85,000 Americans are diagnosed with bladder cancer, and about 17,500 individuals die from the disease. Urothelial carcinoma is the most frequent type of bladder cancer, constituting over 90% of cases in industrialized nations. Up to two-thirds of advanced urothelial carcinomas are ...
Global Analysis Uncovers Wide Inequalities in Care for Breast, Cervical, and Ovarian Cancers
A major study of three of the most common cancers in women, conducted by the Cancer Survival Group at the London School of Hygiene & Tropical Medicine, found variations in the stage of disease at diagnosis, the type of treatment, and the extent to which treatment was consistent with...
Preneoplastic and Neoplastic Small Lymphocytic Proliferations
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Syed Ali Abutalib, MD, and L. Jeffrey Medeiros, MD, explore the key epidemiologic, pathologic, diagnostic, and prognostic aspects of chronic...
Pembrolizumab Plus Chemotherapy Without Radiotherapy in Unresectable Locally Advanced NSCLC With High PD-L1 Expression
In a Japanese phase II trial (Evolution) reported in The Lancet Oncology, Hata et al found that pembrolizumab plus platinum-based chemotherapy without radiotherapy was active in unresectable locally advanced non–small cell lung cancer (NSCLC) with a PD-L1 tumor proportion score (TPS) ≥ 50%. Study...
Risk Factors for Valvular Heart Disease Among Childhood Cancer Survivors
In a study reported in JAMA Oncology, Glele et al identified potential risk factors for valvular heart disease (VHD) in a European cohort of long-term childhood cancer survivors. Study Details The nested case-control study used data from the PanCareSurFup (PanCare Childhood and Adolescent Cancer...
Biomarker-Driven Apalutamide Therapy for Patients With Recurrent Prostate Cancer
Use of PAM50 subtyping allowed clinicians to determine which patients with recurrent prostate cancer were most likely to benefit from the addition of apalutamide hormonal therapy to salvage radiotherapy, according to findings from the phase II BALANCE trial (NRG GU006). These results were presented ...
Postsurgical ctDNA Testing in Stage III Colon Cancer for Treatment De-escalation
Circulating tumor DNA (ctDNA) was found to be a strong prognostic classifier for patients with stage III colon cancer following surgery, according to findings from the phase II/III DYNAMIC-III trial. Findings from the study presented at the European Society for Medical Oncology (ESMO) Congress 2025 ...
Obesity-Related Cancers Are Rising Among Both Younger and Older Adults Worldwide
Multiple studies have reported increasing rates of cancer in younger adults in individual countries, but have not included an international comparison across countries. To address this limitation, Berrington de Gonzalez et al conducted a surveillance study across 42 countries evaluating cancer...
ESMO Publishes Guidance on Large Language Model Use for Oncology Practice
The European Society for Medical Oncology (ESMO) has released its first set of recommendations for the use of artificial intelligence (AI) large language models in oncology practice, called the ESMO Guidance on the Use of Large Language Models in Clinical Practice (ELCAP). The guidance was...
Reversible TKI in HER2-Mutant NSCLC
The oral targeted therapy sevabertinib led to tumor reduction and manageable side effects in patients with HER2-mutant non–small cell lung cancer (NSCLC), according to data from the phase I/II SOHO-01 clinical trial. Over 70% of the patients studied saw their tumors shrink or disappear. The results ...
RCC: Lenvatinib/Everolimus Extends PFS After PD-1 Inhibition
The combination of lenvatinib and everolimus significantly improved progression-free survival compared with cabozantinib in patients with metastatic clear cell renal cell carcinoma (ccRCC) that has progressed on PD-1 immune checkpoint inhibitors, according to findings from the phase II LenCabo...
VT3989 Demonstrates Antitumor Activity and Tolerability in Refractory Mesothelioma
The first-in-class YAP-TEAD inhibitor VT3989 has demonstrated promising antitumor activity and tolerability in patients with refractory mesothelioma, according to findings from a phase I/II trial presented at the European Society for Medical Oncology (ESMO) Congress 2025 (Abstract 920O) and...
Multidisciplinary Program Doubles Lung Cancer Screening Rates
Researchers have created a roadmap to improve national lung cancer screening rates that doubled lung cancer screening rates through their multidisciplinary lung cancer screening program, according to a study published in NEJM Catalyst. “Our biggest success was not only screening a high percentage...
New Leadership Elected to the American Society of Hematology
The American Society of Hematology (ASH) announced the election of three new members to its Executive Committee for terms starting after the 2025 ASH Annual Meeting, taking place December 6 to 9 in Orlando, Florida. Alison Loren, MD, MSCE, will serve a 1-year term as Vice President followed by...
Cutaneous T-Cell Lymphoma: Use of Durvalumab Alone or With Lenalidomide Under Study in Phase II Trial
In a randomized phase II trial, Christiane Querfeld, MD, PhD, and colleagues investigated the effects of a PD-L1–blocking strategy for targeting both the innate and adaptive immune systems in cutaneous T-cell lymphoma (CTCL). At the 2025 Society of Hematologic Oncology (SOHO) Annual Meeting,1 Dr....
Risk of Colorectal Subsequent Malignant Neoplasms in Childhood Cancer Survivors
In a Childhood Cancer Survivor Study analysis reported in the Journal of Clinical Oncology, Owens et al identified the risks of colorectal subsequent malignant neoplasms (SMNs) associated with colorectal-specific radiotherapy (RT) doses and chemotherapy doses among 5-year survivors of childhood...
Creatine
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Yen Nien (Jason) Hou, PharmD, DiplOM, LAc, and Jyothirmai Gubili, MS, focus...
Ziftomenib in Relapsed or Refractory NPM1-Mutant AML
As reported in the Journal of Clinical Oncology by Wang et al, a phase I/II trial (KOMET-001) has shown activity of the oral menin inhibitor ziftomenib in patients with relapsed or refractory NPM1-mutant acute myeloid leukemia (AML). Study Details In the phase II portion of the trial, 92 patients...
Financial Toxicity Tied to Increased Risk of Mortality Among Patients With Cancer
Patients with cancer who developed financial toxicity and falling credit scores faced higher mortality risks, according to findings from a study presented at the American College of Surgeons (ACS) Clinical Congress 2025 and published in the Journal of the American College of Surgeons. “Our work...
Mastectomy Linked to Worsened Sexual Health and Body Image After Surgery, Study Finds
Although mastectomy is often a necessary and life-saving treatment option for many women with breast cancer, the surgery may contribute to worse sexual health, body image, and several other physical and emotional challenges after surgery, according to a recent systematic review on the effects of...
Considerations on Cancer Drug Development
In the 1940s, the first drugs proven to cause objective responses in human cancers were developed. Mechlorethamine was discovered as a possible treatment of lymphoid cancers after autopsies on military personnel exposed to mustard gas found destruction of lymphatic tissue and bone marrow....
